ANNOUNCEMENTS
The protein-protein interactions between PD-1 and PD-L1 diminish the immune response of T-cells against tumor cells. Hence, an effective treatment for cancer immunotherapy would be to prevent the binding of PD-L1 to the PD-1 receptor. One of the methods to accomplish this is by identifying small molecules that can bind to PD-L1 proteins expressed by tumor cells and thereby prevent their interaction with PD-1. The chemical databases contain a plethora of molecules that can act as drugs. However, it is not possible to experimentally test all these molecules against a target protein like PD-L1. An effective strategy to identify inhibitor molecules for PD-L1 would be to carry out molecular docking studies. These studies can identify potential drug molecules that can be tested experimentally, and their druglikeness can be tested. In this study, we have carried out a comprehensive molecular docking study of a library of compounds against the PD-L1 protein and identified inhibitor molecules with high affinity.
